Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Lizard King's Trading Swamp -- Ignore unavailable to you. Want to Upgrade?

To: TATRADER who wrote (5550)	3/30/1998 2:43:00 PM
From: LzzrdKing	Read Replies (2) \| Respond to of 7396

back from FL flipped radaf for 3/8 in gicof 9.25, nice break on vol. in mmcn 19.875 in srcl 15.18 in ttilf 6 3/8 in kndl 22.875 sold finl flat, brkt for 3/4, ames flat, prtl for 1. reversal play of day GX, +3 on it since friday. sold 1/2 of kell at 25. nxco looks good

To: TATRADER who wrote (5550)	3/30/1998 6:58:00 PM
From: majormember	Read Replies (1) \| Respond to of 7396

Mark, Read oldie but goodie on SNRS. One Dr. and broker. Message 2293378 Listen to me; keep SNRS for long term $$$. It WILL get to min. $35+ upon FDA approval (a given). When you see a 20% correction coming, then, but only then sell and rebuy MORE shares. Friend who spent 40 yr. on NYSE floor isn't trading SNRS at all, because he says TA guys don't make the BIG money. The ONLY COMPETETION SNRS HAS ARE GLASSES AND CONTACT LENSES. Review your VISX/BEAM charts. SNRS has a far larger market then either, and it won't tank like BEAM who set up eye centers to compete with their own Dr.'s This is going to be a monster when it gets listed on NASDAQ and can be recommended by major houses. FROM: Business Wire, 11/09/90: VISX talks about their enrollment of patients in their Phase II-B clinical studies, then goes on to state: "Dr. Peter McDonald, director of the cornea service at the Doheny Eye Institute at Univ. of Southern CA performed the first area ablation procedure for the correction of astigmatism." McDonald, who is one of the company's principal investigators, reported his preliminary results at the annual meeting of the American Academy of Ophthamology, held in Atlanta last week. Now you move up two notches in your stock contest if you guess who the principal clinician and major financial backer of the recent 9.85 MIL financing package SNRS just got to see them through FDA approval. Anyway, I'm off to the bar, for what else, a Tequila SUNRISE... Best wishes, Skane P.S. e-mail my profile & I'll FAX you research from Red Chip's Sr. Analyst Johnny Svoren (who now works for H & Q) and Penn. Merchant Gp. (great report).